SG11202112909SA - Method of providing safe administration of an anti-cd40 antibody - Google Patents

Method of providing safe administration of an anti-cd40 antibody

Info

Publication number
SG11202112909SA
SG11202112909SA SG11202112909SA SG11202112909SA SG11202112909SA SG 11202112909S A SG11202112909S A SG 11202112909SA SG 11202112909S A SG11202112909S A SG 11202112909SA SG 11202112909S A SG11202112909S A SG 11202112909SA SG 11202112909S A SG11202112909S A SG 11202112909SA
Authority
SG
Singapore
Prior art keywords
antibody
providing safe
safe administration
administration
providing
Prior art date
Application number
SG11202112909SA
Other languages
English (en)
Inventor
Michael Streit
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11202112909SA publication Critical patent/SG11202112909SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202112909SA 2019-05-28 2020-05-27 Method of providing safe administration of an anti-cd40 antibody SG11202112909SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962853488P 2019-05-28 2019-05-28
PCT/IB2020/055023 WO2020240434A1 (fr) 2019-05-28 2020-05-27 Procédé de fourniture d'une administration sûre d'un anticorps anti-cd40

Publications (1)

Publication Number Publication Date
SG11202112909SA true SG11202112909SA (en) 2021-12-30

Family

ID=70918772

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112909SA SG11202112909SA (en) 2019-05-28 2020-05-27 Method of providing safe administration of an anti-cd40 antibody

Country Status (13)

Country Link
US (1) US20230174658A1 (fr)
EP (1) EP3976651A1 (fr)
JP (1) JP2022534494A (fr)
KR (1) KR20220012918A (fr)
CN (1) CN113939535A (fr)
AU (1) AU2020284706A1 (fr)
BR (1) BR112021023906A2 (fr)
CA (1) CA3142226A1 (fr)
IL (1) IL288288A (fr)
MA (1) MA56027A (fr)
MX (1) MX2021014572A (fr)
SG (1) SG11202112909SA (fr)
WO (1) WO2020240434A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122355A2 (fr) * 2021-12-24 2023-06-29 Sapience Therapeutics, Inc. Méthodes de traitement ou de prévention de réactions liées à la perfusion

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
CA2957146A1 (fr) * 2014-08-12 2016-02-18 Alligator Bioscience Ab Polytherapies utilisant des anticorps anti-cd40
CN110636861B (zh) * 2017-03-03 2022-07-08 詹森生物科技公司 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法

Also Published As

Publication number Publication date
MA56027A (fr) 2022-04-06
US20230174658A1 (en) 2023-06-08
KR20220012918A (ko) 2022-02-04
BR112021023906A2 (pt) 2022-01-25
AU2020284706A1 (en) 2021-12-16
JP2022534494A (ja) 2022-08-01
MX2021014572A (es) 2022-03-17
EP3976651A1 (fr) 2022-04-06
CN113939535A (zh) 2022-01-14
IL288288A (en) 2022-01-01
CA3142226A1 (fr) 2020-12-03
WO2020240434A1 (fr) 2020-12-03

Similar Documents

Publication Publication Date Title
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3478093A4 (fr) Méthode pour faciliter la maturation du système immunitaire de mammifères
AU2017435893B2 (en) Methods for the administration of certain VMAT2 inhibitors
IL279662A (en) Methods of administration of certain VMAT2 inhibitors
AU2018296471A1 (en) Method for authorizing operation permissions of form field values
GB2585307B (en) Methods and apparatus for assembly of moment connection components
EP3145562A4 (fr) Appareil et procédé pour la préparation et l'administration de composants sanguins
IL287902A (en) Methods of administering certain vmat2 inhibitors
EP3279181A4 (fr) Mélange de composé polymérisable et son procédé de production
EP3399996A4 (fr) Procédés d'administration d'hepcidine
EP3432925A4 (fr) Administration d'un anticorps monoclonal anti-lgr5
EP3893931A4 (fr) Méthodes d'utilisation d'anticorps anti-trem2
EP3842426A4 (fr) Procédé de préparation d'un composé de pyrrolo-amino-pyridazinone et son intermédiaire
EP3654193A4 (fr) Procédé pour autoriser une valeur de champ d'un champ de formulaire au moyen d'un champ de tierce partie
EP3696168A4 (fr) Procédé de préparation de 2-chloro-5-trifluorométhylpyridine
IL288288A (en) Method for providing safe administration of anti-cd40 antibody
EP3947448A4 (fr) Procédé d'administration d'un anticorps anti-ifn-alpha/-oméga
EP3766874A4 (fr) Procédé de préparation d'un dérivé d'hexahydrofuro-furan-ol et d'intermédiaire du dérivé, et procédé de préparation associé
EP3589321A4 (fr) Procédé et composé pour modifier l'horloge circadienne
ZA202005380B (en) Method for isolation of cytisine
EP3437681A4 (fr) Appareil d'administration de médicament, procédé d'utilisation d'appareil d'administration de médicament et procédé de fabrication d'appareil d'administration de médicament
SG11202102582TA (en) Method and system of targeting epitopes for neoantigen-based immunotherapy
EP3856246A4 (fr) Procédé pour assurer l'administration sûre d'un anticorps anti-cd154
IL280642A (en) A method for preparing a pharmaceutical formulation for an antibody
IL284086A (en) Controlled Fucosylation of Antibodies